## Ina M Jürgenliemk-Schulz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9532206/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 295-309.	5.1	426
2	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clinical and Translational Radiation Oncology, 2018, 9, 48-60.	0.9	415
3	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, The, 2019, 20, 1273-1285.	5.1	305
4	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials. European Journal of Cancer, 2015, 51, 1742-1750.	1.3	273
5	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncology, The, 2021, 22, 538-547.	5.1	268
6	Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiotherapy and Oncology, 2016, 120, 441-446.	0.3	252
7	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	3.0	229
8	Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiotherapy and Oncology, 2016, 120, 412-419.	0.3	198
9	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 2002-2007.	1.2	135
10	Feasibility of stereotactic radiotherapy using a 1.5â€⁻T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. Radiotherapy and Oncology, 2019, 134, 50-54.	0.3	116
11	MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiotherapy and Oncology, 2009, 93, 322-330.	0.3	109
12	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 797-809.	0.4	96
13	No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. Journal of Clinical Oncology, 2015, 33, 1640-1646.	0.8	83
14	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1088-1098.	0.4	77
15	Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 895-902.	0.4	62
16	Prevention of pterygium recurrence by postoperative single-dose β-irradiation: a prospective randomized clinical double-blind trial. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1138-1147.	0.4	60
17	Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials. International Journal of Radiation Oncology Biology Physics, 2015, 91, 530-539.	0.4	59
18	Variation of treatment planning parameters (D90 HR-CTV, D2cc for OAR) for cervical cancer tandem ring brachytherapy in a multicentre setting: Comparison of standard planning and 3D image guided optimisation based on a joint protocol for dose–volume constraints. Radiotherapy and Oncology, 2010, 94, 339-345.	0.3	56

#	Article	IF	CITATIONS
19	Ring Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2020, 106, 1052-1062.	0.4	51
20	Image Guided Adaptive Brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome. Radiotherapy and Oncology, 2016, 120, 365-369.	0.3	50
21	Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer. Acta Oncológica, 2015, 54, 1567-1573.	0.8	47
22	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. Journal of the National Cancer Institute, 2021, 113, 1212-1220.	3.0	47
23	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	5.8	47
24	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	1.6	45
25	Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiotherapy and Oncology, 2019, 134, 185-190.	0.3	41
26	Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II. International Journal of Radiation Oncology Biology Physics, 2019, 104, 885-894.	0.4	39
27	Quality assurance in MR image guided adaptive brachytherapy for cervical cancer: Final results of the EMBRACE study dummy run. Radiotherapy and Oncology, 2015, 117, 548-554.	0.3	37
28	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiotherapy and Oncology, 2021, 159, 146-154.	0.3	37
29	Vaginal dose de-escalation in image guided adaptive brachytherapy for locally advanced cervical cancer. Radiotherapy and Oncology, 2016, 120, 480-485.	0.3	33
30	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 312-320.	0.3	33
31	Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. Seminars in Radiation Oncology, 2020, 30, 311-327.	1.0	32
32	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 688-700.	0.4	31
33	Internal motion of the vagina after hysterectomy for gynaecological cancer. Radiotherapy and Oncology, 2011, 98, 244-248.	0.3	29
34	Patterns of care survey: Radiotherapy for women with locally advanced cervical cancer. Radiotherapy and Oncology, 2017, 123, 306-311.	0.3	26
35	Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer. Radiotherapy and Oncology, 2014, 111, 442-445.	0.3	24
36	Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, 168-177.	0.4	24

#	Article	IF	CITATIONS
37	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 300-308.	0.3	23
38	Intra-fraction uncertainties of MRI guided brachytherapy in patients with cervical cancer. Radiotherapy and Oncology, 2014, 112, 217-220.	0.3	21
39	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 975-986.	0.4	20
40	Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 400-413.	0.4	20
41	Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers. Frontiers in Oncology, 2021, 11, 628131.	1.3	14
42	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. International Journal of Radiation Oncology Biology Physics, 2022, 112, 681-693.	0.4	14
43	Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. Radiotherapy and Oncology, 2021, 155, 151-159.	0.3	13
44	Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. Radiotherapy and Oncology, 2019, 133, 149-155.	0.3	12
45	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 163, 150-158.	0.3	12
46	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 390-399.	0.4	12
47	Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis. Gynecologic Oncology, 2022, 164, 667-674.	0.6	12
48	Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. Practical Radiation Oncology, 2015, 5, e557-e565.	1.1	11
49	Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases. Radiotherapy and Oncology, 2021, 154, 110-117.	0.3	11
50	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. Gynecologic Oncology, 2021, 163, 117-124.	0.6	11
51	Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. Radiotherapy and Oncology, 2022, 168, 8-15.	0.3	11
52	Indocyanine green versus technetiumâ€99m with blue dye for sentinel lymph node detection in earlyâ€stage cervical cancer: A systematic review and metaâ€analysis. Cancer Reports, 2022, 5, e1401.	0.6	10
53	Cervical cancer apparent diffusion coefficient values during external beam radiotherapy. Physics and Imaging in Radiation Oncology, 2019, 9, 77-82.	1.2	9
54	Progression-free survival in patients with <sup>68</sup> Ga-PSMA-PET-directed SBRT for lymph node oligometastases. Acta Oncológica, 2021, 60, 1342-1351.	0.8	9

#	Article	IF	CITATIONS
55	The feasibility of semi-automatically generated red bone marrow segmentations based on MR-only for patients with gynecologic cancer. Radiotherapy and Oncology, 2017, 123, 164-168.	0.3	8
56	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	8.3	8
57	Vaginal dose-surface maps in cervical cancer brachytherapy: Methodology and preliminary results on correlation with morbidity. Brachytherapy, 2021, 20, 565-575.	0.2	7
58	Comparison of Library of Plans with two daily adaptive strategies for whole bladder radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 20, 82-87.	1.2	7
59	Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 379-389.	0.4	7
60	First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Technical Innovations and Patient Support in Radiation Oncology, 2022, 22, 50-54.	0.6	7
61	Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. Radiotherapy and Oncology, 2021, 157, 24-31.	0.3	6
62	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1177-1189.	0.4	6
63	Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists. Cancers, 2022, 14, 906.	1.7	4
64	Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. Gynecologic Oncology, 2021, 161, 727-733.	0.6	2
65	Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study. Gynecologic Oncology, 2022, 165, 339-346.	0.6	1
66	Response to Yuce Sari et al Radiotherapy and Oncology, 2021, 158, 323-324.	0.3	0